PL2563385T3 - Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów - Google Patents

Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów

Info

Publication number
PL2563385T3
PL2563385T3 PL11778000T PL11778000T PL2563385T3 PL 2563385 T3 PL2563385 T3 PL 2563385T3 PL 11778000 T PL11778000 T PL 11778000T PL 11778000 T PL11778000 T PL 11778000T PL 2563385 T3 PL2563385 T3 PL 2563385T3
Authority
PL
Poland
Prior art keywords
therapy
soluble
methods
rheumatoid arthritis
rheumatoid
Prior art date
Application number
PL11778000T
Other languages
English (en)
Polish (pl)
Inventor
Xincheng Zheng
Wei Wu
Yang Liu
Pan Zheng
Original Assignee
Oncoimmune Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc. filed Critical Oncoimmune Inc.
Publication of PL2563385T3 publication Critical patent/PL2563385T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11778000T 2010-04-28 2011-04-28 Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów PL2563385T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EP11778000.7A EP2563385B1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
PL2563385T3 true PL2563385T3 (pl) 2018-04-30

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11778000T PL2563385T3 (pl) 2010-04-28 2011-04-28 Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów
PL17183045T PL3260128T3 (pl) 2010-04-28 2011-04-28 Zastosowanie medyczne rozpuszczalnego CD24

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17183045T PL3260128T3 (pl) 2010-04-28 2011-04-28 Zastosowanie medyczne rozpuszczalnego CD24

Country Status (17)

Country Link
US (1) US8808697B2 (enExample)
EP (3) EP3260128B1 (enExample)
JP (5) JP5899206B2 (enExample)
KR (1) KR20130086126A (enExample)
CN (2) CN102869369B (enExample)
AU (1) AU2011248540B2 (enExample)
CA (1) CA2795823C (enExample)
DK (1) DK2563385T3 (enExample)
EA (2) EA036805B8 (enExample)
ES (2) ES2645262T3 (enExample)
IL (1) IL222739A0 (enExample)
NO (1) NO2563385T3 (enExample)
NZ (1) NZ603196A (enExample)
PL (2) PL2563385T3 (enExample)
PT (2) PT3260128T (enExample)
SG (1) SG184907A1 (enExample)
WO (1) WO2011139820A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EA038520B1 (ru) * 2015-05-07 2021-09-09 Онкоиммьюн, Инк. Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности
US10799558B2 (en) * 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
CN110650749A (zh) * 2017-05-15 2020-01-03 肿瘤免疫股份有限公司 使用可溶性cd24进行神经保护和髓鞘再生的方法
EP3630158B1 (en) * 2017-05-22 2022-07-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
BR112020024659A2 (pt) * 2018-06-04 2021-03-09 Oncoimmune, Inc. Métodos de uso de cd24 para a prevenção e tratamento de recaída de leucemia
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
EP4251130A4 (en) * 2020-11-30 2024-12-11 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
WO2023051480A1 (en) * 2021-09-28 2023-04-06 Acroimmune Guangzhou Biotech Ltd Fusion proteins comprising 071 core peptide and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
BR0207267A (pt) * 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
PL367329A1 (en) * 2001-07-13 2005-02-21 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
DK1569685T3 (da) * 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
NO2563385T3 (enExample) 2017-12-30
WO2011139820A8 (en) 2013-02-07
JP2015187162A (ja) 2015-10-29
JP2019151655A (ja) 2019-09-12
CN105381451B (zh) 2021-03-09
EP3260128B1 (en) 2020-07-29
HK1176007A1 (zh) 2013-07-19
EP2563385B1 (en) 2017-08-02
CA2795823A1 (en) 2011-11-10
EA036805B8 (ru) 2021-02-25
ES2645262T3 (es) 2017-12-04
PT2563385T (pt) 2017-11-10
IL222739A0 (en) 2012-12-31
JP6888221B2 (ja) 2021-06-16
JP2013527168A (ja) 2013-06-27
JP6526872B2 (ja) 2019-06-05
PT3260128T (pt) 2020-10-22
EP2563385A4 (en) 2013-10-02
AU2011248540B2 (en) 2014-11-20
DK2563385T3 (da) 2017-11-06
NZ603196A (en) 2014-07-25
JP2018127493A (ja) 2018-08-16
SG184907A1 (en) 2012-11-29
EP2563385A1 (en) 2013-03-06
EA201290961A1 (ru) 2013-04-30
PL3260128T3 (pl) 2021-02-08
HK1222554A1 (zh) 2017-07-07
WO2011139820A1 (en) 2011-11-10
JP2017057216A (ja) 2017-03-23
ES2826445T3 (es) 2021-05-18
CN102869369B (zh) 2016-05-18
EA201790538A3 (ru) 2017-11-30
EA036805B1 (ru) 2020-12-23
CN102869369A (zh) 2013-01-09
JP6062502B2 (ja) 2017-01-18
KR20130086126A (ko) 2013-07-31
US8808697B2 (en) 2014-08-19
EA027735B1 (ru) 2017-08-31
JP5899206B2 (ja) 2016-04-06
US20130136739A1 (en) 2013-05-30
EA201790538A2 (ru) 2017-07-31
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
CN105381451A (zh) 2016-03-09
EP3845238A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
PL2563385T3 (pl) Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
GB201106527D0 (en) Therapeutic apparatus
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
GB201014633D0 (en) Rheumatoid arthritis treatment
AP2014007481A0 (en) Method and device for the synthesis of artemisinin
EP2600170A4 (en) RADAR DEVICE
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2629396A4 (en) LOADING APPARATUS
EP2659225A4 (en) DISTANCE MEASURING APPARATUS
PL2578488T3 (pl) Urządzenie do pionowego łączenia dwóch odcinków łańcucha
GB201014546D0 (en) Medico-surgical apparatus
TWM387438U (en) Sliding apparatus
GB201006533D0 (en) Docking apparatus
GB201016864D0 (en) Therapeutic methods
TWM388826U (en) Sliding apparatus
IL286709A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
TWM388828U (en) Sliding apparatus
GB201016659D0 (en) Levelling apparatus
GB201016426D0 (en) Hydrocyclone apparatus
GB201014547D0 (en) Medical analysis apparatus
PL391318A1 (pl) Sposób wytwarzania nanokrystalicznych tlenofluorków lantanowców
GB201007801D0 (en) Telemetry apparatus
GB201020099D0 (en) Subsea apparatus